Paula Renata Lima Machado

Paula Renata Lima Machado

Auto-generated profile, based on publicly available information

Paula Renata Lima Machado

Federal University of Rio Grande do Norte, Brazil

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2014 in Microbiology and Immunology
Verified
Journal Article
Closed access
PDF file
KFKleber Farias
Kleber Farias
PMPaula Renata Lima Machado
Paula Renata Lima Machado
RJRenato Ferreira de Almeida Junior
Renato Ferreira de Almeida Junior
AAAna Alice de Aquino
Ana Alice de Aquino
BFBENEDITO A L da FONSECA
BENEDITO A L da FONSECA

1 April 2015 in Viral Immunology
Verified
Journal Article
Closed access
KFKleber Juvenal Silva Farias
Kleber Juvenal Silva Farias
PMPaula Renata Lima Machado
Paula Renata Lima Machado
JMJosé Augusto Pereira Carneiro Muniz
José Augusto Pereira Carneiro Muniz
AIAline Amaral Imbeloni
Aline Amaral Imbeloni
BFBENEDITO A L da FONSECA
BENEDITO A L da FONSECA
Dengue virus (DENV) of the Flaviviridae family is a single positive-stranded RNA virus that is transmitted by Aedes aegypti and Aedes albopictus mosquitoes. The objective of this study was to investigate the use of chloroquine (CLQ) as an antiviral drug against dengue virus in monkeys. To analyze the action of the drug in vivo, nonhuman primates groups (Aotus azarai infulatus) were inoculated with a subcutaneous injection of a virulent strain of DENV-2, treated and untreated CLQ. Blood hematological, viremia, and serum biochemical values were obtained from 16 DENV-2-inoculated, treated and untreated; four received only CLQ and one mock-infected Aotus monkeys. Monkey serum samples (day 0-10 post-inoculation) were assayed by reverse transcription polymerase chain reaction and Cytometric Bead Array for determination of viremia and inflammatory cytokines, respectively. Additionally, body temperature and activity levels were determined. In the present work, CLQ was effective on replication of DENV-2 in Aotus monkeys; a time viremia reduction was observed compared with the controls. The concentration of tumor necrosis factor alpha and interferon gamma in the serum of the animals had a statistically significant reduction in the groups treated with CLQ after infection compared with the controls. A significant decrease in systemic levels of the liver enzyme aspartate aminotransferase (AST) was also observed in the animals treated with CLQ after infection compared with the controls. These results suggest that CLQ interferes in DENV-2 replication in Aotus monkeys.

31 January 2013 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
KFKleber Farias
Kleber Farias
PMPaula Renata Lima Machado
Paula Renata Lima Machado
BFBENEDITO A L da FONSECA
BENEDITO A L da FONSECA
Dengue viruses are the most important arthropod‐borne viruses in terms of morbidity and mortality in the world. Since there is no dengue vaccine available for human use, we have set out to investigate the use of chloroquine as an antiviral drug against dengue. Chloroquine, an amine acidotropic drug known to affect intracellular exocytic pathways by increasing endosomal pH, was used in the in vitro treatment of Vero and C6/36 cells infected with dengue virus type 2 (DENV‐2). Real‐time RT‐PCR and plaque assays were used to quantify the DENV‐2 load in infected Vero and C6/36 cells after chloroquine treatment. Our results showed that a dose of 50 μg/ml of chloroquine was not toxic to the cells and induced a statistically significant inhibition of virus production in infected Vero cells when compared to untreated cells. In C6/36 cells, chloroquine does not induce a statistically significant difference in viral replication when compared to untreated cells, showing that this virus uses an unlikely pathway of penetration in these cells, and results were also confirmed by the plaque assay (PFU). These data suggest that the inhibition of virus infection induced by chloroquine is due to interference with acidic vesicles in mammalian cells.

1 June 2015 in Peptides
Verified
Journal Article
Closed access
EMEdinara Targino de Melo
Edinara Targino de Melo
AEAndréia Bergamo Estrela
Andréia Bergamo Estrela
ESElizabeth Santos
Elizabeth Santos
PMPaula Renata Lima Machado
Paula Renata Lima Machado
KFKleber Juvenal Silva Farias
Kleber Juvenal Silva Farias
MPMatheus Pedrosa
Matheus Pedrosa

3 December 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TLTábata Lima
Tábata Lima
RFRenata De Carvalho Feitosa
Renata De Carvalho Feitosa
ESEmanuell dos Santos Silva
Emanuell dos Santos Silva
ASAlaine Maria dos Santos-Silva
Alaine Maria dos Santos-Silva
ESEmerson Michell da Silva Siqueira
Emerson Michell da Silva Siqueira
Arnobio Antonio Da Silva-JuniorArnobio Antonio Da Silva-Junior
Arnobio Antonio Da Silva-Junior
Chloroquine diphosphate (CQ) is a hydrophilic drug with low entrapment efficiency in hydrophobic nanoparticles (NP). Herpes simplex virus type 1 (HSV-1) is an enveloped double-stranded DNA virus worldwide known as a common human pathogen. This study aims to develop chloroquine-loaded poly(lactic acid) (PLA) nanoparticles (CQ-NP) to improve the chloroquine anti- HSV-1 efficacy. CQ-NP were successfully prepared using a modified emulsification-solvent evaporation method. Physicochemical properties of the NP were monitored using dynamic light scattering, atomic force microscopy, drug loading efficiency, and drug release studies. Spherical nanoparticles were produced with modal diameter of <300 nm, zeta potential of −20 mv and encapsulation efficiency of 64.1%. In vitro assays of CQ-NP performed in Vero E6 cells, using the MTT-assay, revealed different cytotoxicity levels. Blank nanoparticles (B-NP) were biocompatible. Finally, the antiviral activity tested by the plaque reduction assay revealed greater efficacy for CQ-NP compared to CQ at concentrations equal to or lower than 20 µg mL−1 (p < 0.001). On the other hand, the B-NP had no antiviral activity. The CQ-NP has shown feasible properties and great potential to improve the antiviral activity of drugs.

23 June 2010 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
LCLuiza A. Castro‐Jorge
Luiza A. Castro‐Jorge
PMPaula R.L. Machado
Paula R.L. Machado
CFCamila A. Fávero
Camila A. Fávero
MBMarcos Carvalho Borges
Marcos Carvalho Borges
LPLuzia M.R. Passos
Luzia M.R. Passos
BFBENEDITO A L da FONSECA
BENEDITO A L da FONSECA